These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35697777)

  • 1. P2Y
    Capodanno D; Baber U; Bhatt DL; Collet JP; Dangas G; Franchi F; Gibson CM; Gwon HC; Kastrati A; Kimura T; Lemos PA; Lopes RD; Mehran R; O'Donoghue ML; Rao SV; Rollini F; Serruys PW; Steg PG; Storey RF; Valgimigli M; Vranckx P; Watanabe H; Windecker S; Angiolillo DJ
    Nat Rev Cardiol; 2022 Dec; 19(12):829-844. PubMed ID: 35697777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin-free antiplatelet strategies after percutaneous coronary interventions.
    Capranzano P; Moliterno D; Capodanno D
    Eur Heart J; 2024 Feb; 45(8):572-585. PubMed ID: 38240716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y
    Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M;
    J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
    Wu XT; He RR; Liang SZ; Ye GY; Ding SB
    Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation.
    Verheugt FWA; Huber K; Clemmensen P; Collet JP; Cuisset T; Andreotti F
    Thromb Haemost; 2023 Feb; 123(2):159-165. PubMed ID: 36584699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.
    Nicolas J; Dangas G; Chiarito M; Pivato CA; Spirito A; Cao D; Giustino G; Beerkens F; Camaj A; Vogel B; Sartori S; Yamamoto K; Kimura T; Kim BK; Baber U; Mehran R
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):240-250. PubMed ID: 36564015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
    Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
    Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y
    Andò G; De Santis GA; Greco A; Pistelli L; Francaviglia B; Capodanno D; De Caterina R; Capranzano P
    JACC Cardiovasc Interv; 2022 Nov; 15(22):2239-2249. PubMed ID: 36423966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with P2Y12 inhibitor monotherapy after PCI according to bleeding risk: A Bayesian meta-analysis.
    Woelders ECI; Luijkx JJP; Rodwell L; Winkler PJC; Dimitriu-Leen AC; Smits PC; van Royen N; Hof AWJV; Damman P; van Geuns RJM
    Cardiovasc Revasc Med; 2023 Oct; 55():44-51. PubMed ID: 37188619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of P2Y
    Galli M; Capodanno D; Andreotti F; Crea F; Angiolillo DJ
    Expert Opin Drug Saf; 2021 Jan; 20(1):9-21. PubMed ID: 33180563
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
    Al-Obaidi FR; Hutchings HA; Yong ASC; Alrubaiy L; Al-Farhan H; Al-Ali MH; Al-Kinani T; Al-Myahi M; Al-Kenzawi H; Al-Sudani N
    Curr Cardiol Rev; 2021; 17(6):e051121190712. PubMed ID: 33573571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.
    Ho MY; Chen PW; Feng WH; Su CH; Huang SW; Cheng CW; Yeh HI; Chen CP; Huang WC; Fang CC; Lin HW; Lin SH; Hsieh IC; Li YH
    PLoS One; 2021; 16(5):e0251109. PubMed ID: 33979377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Takagi H; Bangalore S
    Am Heart J; 2020 Sep; 227():82-90. PubMed ID: 32693196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
    Alkhalil M; Džavík V; Bhatt DL; Mehran R; Mehta SR
    Curr Cardiol Rep; 2022 Mar; 24(3):277-293. PubMed ID: 35294730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
    Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.